Angiotensin-Converting Enzyme 2 Metabolizes and Partially Inactivates Pyr-Apelin-13 and Apelin-17: Physiological Effects in the Cardiovascular System

Hypertension

Volumn 68, Issue 2, 2016, Pages 365-377

  Wang, Wang ^a,b   McKinnie, Shaun M K ^b   Farhan, Maikel ^b   Paul, Manish ^c   McDonald, Tyler ^b   McLean, Brent ^a,b   Llorens Cortes, Catherine ^d   Hazra, Saugata ^e   Murray, Allan G ^b   Vederas, John C ^b   Oudit, Gavin Y ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c WEST BENGAL STATE UNIVERSITY   (India)

^d PSL RESEARCH UNIVERSITY   (France)

^e INDIAN INSTITUTE OF TECHNOLOGY ROORKEE   (India)

Author keywords

angiotensin converting enzyme 2; apelin 17; blood pressure; computer based model; enzyme kinetics; ischemia reperfusion injury; pyr apelin 13

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANTIHYPERTENSIVE AGENT; APELIN; APELIN 17; NITRIC OXIDE; PYR APELIN 12; PYR APELIN 13; PYR APELIN 16; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; ADIPOCYTOKINE; APELIN 13, PYR(1)-; APELIN 17 PEPTIDE, HUMAN; APLN PROTEIN, MOUSE; CARDIOTONIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; PROTEIN BINDING; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BIOCHEMICAL ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; DRUG DESIGN; DRUG INHIBITION; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME INHIBITION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; ISOLATED HEART; MALE; MOUSE; MURINE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; REPERFUSION INJURY; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; CARDIOVASCULAR SYSTEM; COMPUTER SIMULATION; DRUG DEVELOPMENT; DRUG EFFECTS; HALF LIFE TIME; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTECTION; VASOCONSTRICTION;

ADIPOKINES; ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR SYSTEM; COMPUTER SIMULATION; DRUG DISCOVERY; HALF-LIFE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MYOCARDIAL REPERFUSION INJURY; PEPTIDYL-DIPEPTIDASE A; PROTECTIVE FACTORS; PROTEIN BINDING; VASOCONSTRICTION;

EID: 84970024448     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06892     Document Type: Article

References (41)

1. Pitkin SL, Maguire JJ, Bonner TI, Davenport AP. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev. 2010;62:331-342. doi: 10.1124/pr.110.002949.
2. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-828. doi: 10.1038/nature00786.
3. Scimia MC, Hurtado C, Ray S, et al. APJ acts as a dual receptor in cardiac hypertrophy. Nature. 2012;488:394-398. doi: 10.1038/nature11263.
4. Sato T, Suzuki T, Watanabe H, Kadowaki A, Fukamizu A, Liu PP, Kimura A, Ito H, Penninger JM, Imai Y, Kuba K. Apelin is a positive regulator of ACE2 in failing hearts. J Clin Invest. 2013;123:5203-5211. doi: 10.1172/ JCI69608.
5. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, Loibner H, Wang XH, Penninger JM, Kassiri Z, Oudit GY. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation. 2010;122:717-728, 718 p following 728. doi: 10.1161/CIRCULATIONAHA.110.955369.
6. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension. 2009;54:598-604. doi: 10.1161/HYPERTENSIONAHA.109.134619.
7. Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, Kitada C, Honda S, Kurokawa T, Onda H, Nishimura O, Fujino M. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem. 2000;275:21061-21067. doi: 10.1074/jbc.M908417199.
8. Wang W, McKinnie SM, Patel VB, Haddad G, Wang Z, Zhabyeyev P, Das SK, Basu R, McLean B, Kandalam V, Penninger JM, Kassiri Z, Vederas JC, Murray AG, Oudit GY. Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues. J Am Heart Assoc. 2013;2:e000249. doi: 10.1161/JAHA.113.000249.
9. Alastalo TP, Li M, Perez Vde J, Pham D, Sawada H, Wang JK, Koskenvuo M, Wang L, Freeman BA, Chang HY, Rabinovitch M. Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest. 2011;121:3735-3746. doi: 10.1172/JCI43382.
10. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J, Johnston NR, Denvir MA, Megson IL, Flapan AD, Newby DE. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation. 2010;121:1818-1827. doi: 10.1161/ CIRCULATIONAHA.109.911339.
11. De Mota N, Reaux-Le Goazigo A, El Messari S, Chartrel N, Roesch D, Dujardin C, Kordon C, Vaudry H, Moos F, Llorens-Cortes C. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci USA. 2004;101:10464-10469.
12. El Messari S, Iturrioz X, Fassot C, De Mota N, Roesch D, Llorens-Cortes C. Functional dissociation of apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure. J Neurochem. 2004;90:1290-1301. doi: 10.1111/j.1471-4159.2004.02591.x.
13. Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, Lawrie KW, Hervieu G, Riley G, Bolaky JE, Herrity NC, Murdock P, Darker JG. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem. 2003;84:1162-1172.
14. Fan X, Zhou N, Zhang X, Mukhtar M, Lu Z, Fang J, DuBois GC, Pomerantz RJ. Structural and functional study of the apelin-13 peptide, an endogenous ligand of the HIV-1 coreceptor, APJ. Biochemistry. 2003;42:10163-10168. doi: 10.1021/bi030049s.
15. Iturrioz X, Gerbier R, Leroux V, Alvear-Perez R, Maigret B, Llorens-Cortes C. By interacting with the C-terminal Phe of apelin, Phe255 and Trp259 in helix VI of the apelin receptor are critical for internalization. J Biol Chem. 2010;285:32627-32637. doi: 10.1074/jbc. M110.127167.
16. Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T, Ryan D, Fisher M, Williams D, Dales NA, Patane MA, Pantoliano MW. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem. 2004;279:17996-18007. doi: 10.1074/jbc.M311191200.
17. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. J Comput Chem. 2005;26:1701-1718. doi: 10.1002/jcc.20291.
18. Guy JL, Jackson RM, Jensen HA, Hooper NM, Turner AJ. Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis. FEBS J. 2005;272:3512-3520. doi: 10.1111/j.1742-4658.2005.04756.x.
19. Guy JL, Jackson RM, Acharya KR, Sturrock ED, Hooper NM, Turner AJ. Angiotensin-converting enzyme-2 (ace2): Comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry. 2003;42:13185-13192.
20. Dales NA, Gould AE, Brown JA, Calderwood EF, Guan B, Minor CA, Gavin JM, Hales P, Kaushik VK, Stewart M, Tummino PJ, Vickers CS, Ocain TD, Patane MA. Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc. 2002;124:11852-11853.
21. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455-461. doi: 10.1002/ jcc.21334.
22. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60(pt 12 pt 1):2126-2132. doi: 10.1107/S0907444904019158.
23. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins. 2006;65:712-725. doi: 10.1002/ prot.21123.
24. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605-1612. doi: 10.1002/jcc.20084.
25. The PyMOL Molecular Graphics System, Version 1.8. Schrödinger, LLC. http://www.pymol.org/citing. Accessed May 12, 2016.
26. Patel VB, Bodiga S, Basu R, Das SK, Wang W, Wang Z, Lo J, Grant MB, Zhong J, Kassiri Z, Oudit GY. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ Res. 2012;110:1322-1335. doi: 10.1161/ CIRCRESAHA.112.268029.
27. Cervenka L, Wang CT, Navar LG. Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats. Am J Physiol. 1998;274(5 Pt 2):F940-F945.
28. Ye M, Wysocki J, Gonzalez-Pacheco FR, Salem M, Evora K, Garcia-Halpin L, Poglitsch M, Schuster M, Batlle D. Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. Hypertension. 2012;60:730-740. doi: 10.1161/HYPERTENSIONAHA. 112.198622.
29. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838-14843. doi: 10.1074/jbc.M200581200.
30. Wang W, Patel VB, Parajuli N, Fan D, Basu R, Wang Z, Ramprasath T, Kassiri Z, Penninger JM, Oudit GY. Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease. J Mol Med (Berl). 2014;92:847-858. doi: 10.1007/s00109-014-1149-y.
31. Zhang QX, Nakhaei-Nejad M, Haddad G, Wang X, Loutzenhiser R, Murray AG. Glomerular endothelial PI3 kinase-α couples to VEGFR2, but is not required for eNOS activation. Am J Physiol Renal Physiol. 2011;301:F1242-F1250. doi: 10.1152/ajprenal.00662.2010.
32. Zhong JC, Yu XY, Huang Y, Yung LM, Lau CW, Lin SG. Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res. 2007;74:388-395. doi: 10.1016/j.cardiores.2007.02.002.
33. Kidoya H, Naito H, Takakura N. Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia. Blood. 2010;115:3166-3174. doi: 10.1182/blood-2009-07-232306.
34. Murza A, Parent A, Besserer-Offroy E, Tremblay H, Karadereye F, Beaudet N, Leduc R, Sarret P, Marsault É. Elucidation of the structureactivity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability. ChemMedChem. 2012;7:318-325. doi: 10.1002/cmdc.201100492.
35. Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, Putko B, Kassiri Z, Turner AJ, Oudit GY. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J Mol Cell Cardiol. 2014;66:167-176. doi: 10.1016/j.yjmcc.2013.11.017.
36. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensinconverting enzyme-2 (ACE2). J Biol Chem. 2005;280:30113-30119. doi: 10.1074/jbc.M505111200.
37. Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, Krähenbühl S. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet. 2013;52:783-792. doi: 10.1007/ s40262-013-0072-7.
38. Lo J, Patel VB, Wang Z, Levasseur J, Kaufman S, Penninger JM, Oudit GY. Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats. Exp Physiol. 2013;98:109-122. doi: 10.1113/expphysiol.2012.067165.
39. Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, Fujimiya M. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99:87-92.
40. Busch R, Strohbach A, Pennewitz M, Lorenz F, Bahls M, Busch MC, Felix SB. Regulation of the endothelial apelin/APJ system by hemodynamic fluid flow. Cell Signal. 2015;27:1286-1296. doi: 10.1016/j.cellsig.2015.03.011.
41. Ceraudo E, Galanth C, Carpentier E, Banegas-Font I, Schonegge AM, Alvear-Perez R, Iturrioz X, Bouvier M, Llorens-Cortes C. Biased signaling favoring gi over β-arrestin promoted by an apelin fragment lacking the C-terminal phenylalanine. J Biol Chem. 2014;289:24599-24610. doi: 10.1074/jbc.M113.541698.